Article
Low-dose Epidermal Growth Factor Receptor (EGFR)- Tyrosine Kinase Inhibition of EGFR Mutation-positive Lung Cancer: Therapeutic Benefits and Associations Between Dosage, Efficacy and Body Surface Area.
Asian Pacific journal of cancer prevention : APJCP - 1 Jan 2016
Hirano Ryosuke, Uchino Junji, Ueno Miho, Fujita Masaki, Watanabe Kentaro
Abstract excerpt
A key drug for treatment of EGFR mutation-positive non-small cell lung cancer is epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). While the dosage of many general anti-tumor drugs is adjusted according to the patient body surface area, one uniform dose of most TKIs is recommended regardless of body size. In many cases, dose reduction or drug cessation is necessary due to adverse effects....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.